Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

被引：2
|
作者：
Bhatia, Aarti K.
Mehra, Ranee
Khan, Saad A.
Egleston, Brian L.
Alpaugh, R. Katherine
Lango, Miriam
Ridge, John A.
Burtness, Barbara
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6027
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Paclitaxel and carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. A phase II study.
    Hiller, S
    Mergenthaler, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [2] A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Enokida, Tomohiro
    Ogawa, Takenori
    Homma, Akihiro
    Okami, Kenji
    Minami, Shujiro
    Nakanome, Ayako
    Shimizu, Yasushi
    Maki, Daisuke
    Ueda, Yuri
    Fujisawa, Takao
    Motegi, Atsushi
    Ohkoshi, Akira
    Taguchi, Jun
    Ebisumoto, Koji
    Nomura, Shogo
    Okano, Susumu
    Tahara, Makoto
    CANCER MEDICINE, 2020, 9 (05): : 1671 - 1682
  • [3] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [4] Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)
    Wanebo, H. J.
    Lee, J.
    Burtness, B. A.
    Ridge, J. A.
    Ghebremichael, M.
    Spencer, S. A.
    Psyrri, D.
    Pectasides, E.
    Rimm, D.
    Rosen, F. R.
    Hancock, M. R.
    Tolba, K. A.
    Forastiere, A. A.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 2036 - 2041
  • [5] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [6] High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Chauffert, Bruno
    Zhou, Yuedan
    Medjkoune, Liza
    Ouikene, Abdenour
    Galez, Agnes
    Belkhir, Farid
    Saint-Germain, Pierre
    Youssef, Ali
    Chehimi, Mohamad
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 13 - 20
  • [7] Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
    Pivot, X
    Cals, L
    Cupissol, D
    Guardiola, E
    Tchiknavorian, X
    Guerrier, P
    Merad, L
    Wendling, JL
    Barnouin, L
    Savary, J
    Thyss, A
    Schneider, M
    ONCOLOGY, 2001, 60 (01) : 66 - 71
  • [8] A multicenter phase II trial of paclitaxel, carboplatin and cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Enokida, T.
    Ogawa, T.
    Homma, A.
    Okami, K.
    Minami, S.
    Iwae, S.
    Nakanome, A.
    Shimizu, Y.
    Motegi, A.
    Maki, D.
    Ueda, Y.
    Fujisawa, T.
    Nomura, S.
    Okano, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Phase II study of cetuximab and lenalidomide in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Taylor, Rodney J.
    Saloura, Vassiliki
    Wong, Richard
    Goloubeva, Olga
    Silpino, Lorna
    de Souza, Jonas
    Seiwert, Tanguy
    Vokes, Everett
    Cohen, Ezra
    Villaflor, Victoria
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [10] Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
    Friesland, Signe
    Tsakonas, Georgios
    Kristensen, Claus
    Moren, Maria Herlestam Calero
    Haugen, Hedda
    Soderstrom, Karin
    Specht, Lena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345